SCHEMBL6323328

SCHEMBL6323328

CC1OC(=O)OC1(C)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867338 0.78
SCHEMBL10998035 0.76
SCHEMBL12128239 0.75
SCHEMBL4838834 0.75
SCHEMBL20085537 0.71
SCHEMBL9135118 0.69 SMN1; SMN2 (0.33)
SCHEMBL29596295 0.68
SCHEMBL2871130 0.68
SCHEMBL21064149 0.68
SCHEMBL471952 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050070515-A1 Compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-03-31 US disclosed
EP-0998484-B1 METHOD OF IDENTIFYING COMPOUNDS HAVING REDUCED SYSTEMIC EFFECTS GLAXO GROUP LTD (GB) 2004-03-03 EP disclosed
US-20020019378-A1 COMPOUNDS GLAXO WELLCOME INC. 2002-02-14 US disclosed
EP-0998484-A1 THARAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCED HALF-LIFE GLAXO GROUP LIMITED (GB) 2000-05-10 EP disclosed
WO-1999001467-A2 THERAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCE HALF LIFE GLAXO GROUP LIMITED (GB) 1999-01-14 WO disclosed